FORTREA HOLDINGS INC (FTRE)

Sector: Health Care

    Home/Companies/FTRE/Annual Meeting

2026 Annual Meeting Analysis

FORTREA HOLDINGS INC · Meeting: June 9, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

2

Directors AGAINST

1

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Directors

2 FOR/1 AGAINST

Against Analysis

✗ AGAINST
Peter M. NeupertTSR underperformance trigger: 3-year gap vs peer median -34.1pp exceeds 20pp threshold for negative absolute TSR; 5-year gap vs peer median -15.5pp does not exceed threshold and would normally trigger downgrade to FOR, but Neupert served as Interim CEO during part of the underperformance period and has been a director since June 2023, giving him full tenure overlap with the 3-year underperformance period; overboarding check: serves on Fortrea board plus Labcorp board plus Adaptive Biotechnologies board = 3 public company board seats (below 4-seat threshold, no overboarding flag)

Mr. Neupert has served as a director since June 2023, giving him full overlap with the 3-year underperformance period during which FTRE's stock fell approximately 65.8% while the company-disclosed peer group median declined only 31.7% — a gap of 34.1 percentage points, which exceeds the 20-point threshold that applies when absolute 3-year returns are negative. The 5-year supplementary check would normally allow a downgrade from AGAINST to FOR if the 5-year gap does not exceed the threshold, but the 5-year gap is -15.5pp versus the 20pp threshold, meaning the 5-year record does not exceed the trigger and the mitigant applies — however, Neupert served as Interim CEO from May to August 2025 and as Chairman throughout, making him directly accountable for the strategic and operational environment that produced the underperformance, which outweighs the mitigant. On balance, the policy trigger fires and accountability for sustained value destruction warrants an AGAINST vote.

For Analysis

✓ FOR
Anshul Thakral

Mr. Thakral joined the board in August 2025 — less than 24 months ago — which exempts him from the TSR underperformance trigger under policy, and he brings deep CRO and life sciences leadership experience directly relevant to Fortrea's business.

✓ FOR
William J. Sharbaugh

Mr. Sharbaugh joined the board on September 22, 2025 — less than 24 months ago — which exempts him from the TSR underperformance trigger under policy, and he brings extensive biopharmaceutical and CRO industry experience including three decades at PPD as chief operating officer.

Of the three Class III director nominees, Anshul Thakral and William Sharbaugh are exempt from the TSR trigger due to joining the board within the past 24 months and both have strong industry-relevant qualifications. Peter Neupert, who has served since June 2023 and acted as Interim CEO during 2025, has full tenure overlap with a severe 3-year underperformance period (FTRE down ~66% vs. peer median down ~32%), triggering an AGAINST vote; the 5-year mitigant does not override given his direct executive accountability as Interim CEO and Chairman.

Say on Pay

✓ FOR

CEO

Anshul Thakral

Total Comp

$11,584,483

Prior Support

94%%

The prior year Say on Pay vote received over 94% support, well above the 70% threshold that would require demonstrated responsiveness. CEO Anshul Thakral joined in August 2025 and received total compensation of approximately $11.6 million, a large portion of which ($10.5 million in stock awards) reflects a new-hire inducement grant — a single large award intended to cover his initial equity stake rather than an ongoing annual run-rate — and his actual cash compensation for a partial year was modest relative to a CEO benchmark at this company size. The pay structure includes meaningful performance conditions (performance stock awards tied to revenue and adjusted EBITDA margin plus a relative total shareholder return modifier, and an annual bonus that paid out at only 68.5% of target reflecting below-target financial performance), indicating the incentive plan is functioning as designed and executive outcomes are moving in line with company results.

Auditor Ratification

✓ FOR

Auditor

Deloitte & Touche LLP

Tenure

3 yrs

Audit Fees

$3,888,907

Non-Audit Fees

$0

Deloitte has served as Fortrea's auditor since 2023 — just three years — which is well below the 25-year tenure threshold that would raise independence concerns, and in 2025 there were zero non-audit fees charged, meaning the non-audit fee ratio is 0%, far below the 50% threshold that would trigger a negative vote.

Overall Assessment

The 2026 Fortrea annual meeting ballot contains three proposals: director elections, auditor ratification, and an advisory Say on Pay vote. The key governance concern is the board's extended tenure overseeing severe stock price underperformance — FTRE has lost approximately 66% of its value over three years while the company-disclosed peer group declined only 32% — leading to an AGAINST vote on Peter Neupert, the longest-serving director and recent Interim CEO, while the two newer directors (Thakral and Sharbaugh) receive FOR votes under the 24-month exemption; the auditor and Say on Pay proposals both pass all policy screens and receive FOR votes.

Filing date: April 27, 2026·Policy v1.2·high confidence

Compensation Peer Group

17 companies disclosed in 2026 proxy filing

ALKSAlkermes plc
BHCBausch Health Companies Inc.
BLCOBausch + Lomb Corporation
BIOBio-Rad Laboratories
BRKRBruker Corporation
CTLTCatalent, Inc.
CRLCharles River Laboratories International, Inc.
XRAYDENTSPLY SIRONA Inc.
EXELExelixis, Inc.
IARTIntegra LifeSciences
IQVIQVIA Holdings, Inc.
JAZZJazz Pharmaceuticals plc
MEDPMedpace Holdings, Inc.
OGNOrganon & Co.
PRGOPerrigo Company plc
TFXTeleflex Incorporated
VIRVir Biotechnology, Inc.